Nab-paclitaxel: A novel formulation of taxane for treatment of breast cancer

Women's Health

Volumn 6, Issue 4, 2010, Pages 495-506

  Vishnu, Prakash ^a   Roy, Vivek ^a  

^a MAYO CLINIC   (United States)

Author keywords

docetaxel; metastatic breast cancer; nab paclitaxel; nab technology; paclitaxel; taxane

Indexed keywords

ALBUMIN; ANTHRACYCLINE DERIVATIVE; AZACITIDINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CREMOPHOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; IMIQUIMOD; LAPATINIB; NAVELBINE; OSTEONECTIN; PACLITAXEL; PEMETREXED; RAPAMYCIN; TANESPIMYCIN; TRASTUZUMAB; VORINOSTAT;

ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RESEARCH; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ELECTROCARDIOGRAPHY; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; HEART ARREST; HUMAN; INFECTION; KERATOPATHY; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PARTICLE SIZE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIOSENSITIZATION; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNITED STATES; VISUAL IMPAIRMENT; VOMITING;

ALBUMINS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYTOTOXINS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; PACLITAXEL; RADIATION-SENSITIZING AGENTS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954420212     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.42     Document Type: Review

References (28)

1. Kataja V, Castiglione M. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl. 4), 10-14 (2009).
2. Kataja V, Castiglione M: Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 19(Suppl. 2), II11-II13 (2008).
3. De Laurentiis M, Cancello G, D'Agostino D et al.: Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J. Clin. Oncol. 26(1), 44-53 (2008).
4. Sparreboom A, van Zuylen L, Brouwer E et al.: Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 59(7), 1454-1457 (1999) (Pubitemid 29160110)
5. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A: Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 42(7), 665-685 (2003). (Pubitemid 36936530)
6. Dumontet C, Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 17(3), 1061-1070 (1999). (Pubitemid 29109340)
7. van Zuylen L, Karlsson MO, Verweij J et al.: Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother. Pharmacol. 47(4), 309-318 (2001). (Pubitemid 32640770)
8. Winer EP, Berry DA, Woolf S et al.: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: J. Clin. Oncol. 22(11), 2061-2068 (2004).
9. Seidman AD: "Will weekly work"? Seems to be so. J. Clin. Oncol. 23(25), 5873-5874 (2005).
10. Desai N, Trieu V, Yao Z et al.: Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12(4), 1317-1324 (2006). (Pubitemid 43342524)
11. Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ: Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 19(9), 899-909 (2008).
12. Ibrahim NK, Desai N, Legha S et al.: Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8(5), 1038-1044 (2002). (Pubitemid 34517637)
13. Nyman DW, Campbell KJ, Hersh E et al.: Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol. 23(31), 7785-7793 (2005). (Pubitemid 46657375)
14. Gardner ER, Dahut WL, Scripture CD et al.: Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin. Cancer Res. 14(13), 4200-4205 (2008).
15. Stinchcombe TE, Socinski MA, Walko CM et al.: Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother. Pharmacol. 60(5), 759-766 (2007).
16. Chien AJ, Illi JA, Ko AH et al.: A Phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound paclitaxel for advanced solid malignancies. Clin. Cancer Res. 15(17), 5569-5575 (2009).
17. Ibrahim NK, Samuels B, Page R et al.: Multicenter Phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oncol. 23(25), 6019-6026 (2005). (Pubitemid 46300219)
18. Blum JL, Savin MA, Edelman G et al.: Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin. Breast Cancer. 7(11), 850-856 (2007).
19. ®) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann. Oncol. 20(3), 449-453 (2009).
20. Gradishar WJ, Krasnojon D, Cheporov S et al.: Signifcantly longer progression-free survival with nab-paclitaxel compared with docetaxel as frst-line therapy for metastatic breast cancer. J. Clin. Oncol. 27(22), 3611-3619 (2009).
21. Robidoux A, Buzdar AU, Quinaux E et al.: A Phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fuorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin. Breast Cancer. 10(1), 81-86 (2010).
22. Gradishar WJ, Tjulandin S, Davidson N et al.: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23(31), 7794-7803 (2005). (Pubitemid 46657376)
23. Guan Z, Feng F, Li QL et al.: Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, June 20, 2007.
24. Dranitsaris G, Coleman R, Gradishar W: nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as frst-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res. Treat. 119(3), 717-724 (2009).
25. Desai N, Trieu V, Damascelli B, Soon-Shiong P: SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Translational Oncol. 2(2), 59-64 (2009).
26. Green MR, Manikhas GM, Orlov S et al.: Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 17(8), 1263-1268 (2006). (Pubitemid 44288216)
27. Rizvi NA, Riely GJ, Azzoli CG et al.: Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. 26(4), 639-643 (2008).
28. Wiedenmann N, Valdecanas D, Hunter N et al.: 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin. Cancer Res. 13(6), 1868-1874 (2007). (Pubitemid 46952957)